Phase 1 Study of PF-08046876 Given by IV to Adults With Advanced Bladder, Lung, Head and Neck, Esophagus, or Pancreatic Cancers

What this Trial Is About

Researchers are evaluating PF-08046876, an investigational antibody drug conjugate ADC, in adults diagnosed with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. ADCs are designed to target and kill cancer cells specifically. This Phase 1 open-label study aims to explore the safety and effects of this study drug in people with these advanced solid tumors. Participants will receive PF-08046876 through an intravenous infusion. The study includes multiple parts an initial dose escalation phase with different doses and schedules, followed by randomization to two dosing regimens identified as safe in the first part. Tumor-specific groups will receive one safe dosing regimen from the first part. Different groups will receive varied doses and schedules to determine optimal treatment plans. Throughout the study, participants will be monitored for treatment-emergent adverse events and dose-limiting toxicities. Researchers will evaluate response rates, duration of response, progression-free survival, and overall survival for up to several years. Blood samples will assess pharmacokinetics and immune response. Tumor tissue will be analyzed for immune cell changes. Study participation may last multiple years, with safety and response monitored closely during and after treatment.

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors